Nodthera Limited
20 Charlotte Square
Edinburgh
EH2 4DF
About Nodthera Limited
Nodthera Limited is a biotech company focused on the discovery and development of novel inhibitors of the NLRP3 inflammasome.YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Elizabeth Roper, PhD
8 articles about Nodthera Limited
-
NodThera Announces Positive Phase 1 Study Readouts for the NLRP3 Inflammasome Inhibitors NT-0796 and NT-0249
9/21/2022
NodThera, a clinical-stage biotechnology company developing a new class of potent and selective oral, small molecule NLRP3 inflammasome inhibitors to treat diseases driven by chronic inflammation, today announced positive Phase 1 clinical readouts for its first and second clinical candidates, NT-0796 and NT-0249.
-
Sofinnova Partners announced on Monday that it entered into a long-term strategic and financial partnership with Apollo to expand its presence in the life sciences.
-
NodThera Announces Clinical Progress for Lead NLRP3 Inflammasome Inhibitors and Candidate Selection of Novel Brain-Penetrant Compound
5/10/2022
NodThera, a clinical-stage biotechnology company developing a new class of potent and selective oral, small molecule NLRP3 inflammasome inhibitors to treat diseases driven by chronic inflammation, today announced several key advancements across the portfolio. NodThera's lead candidate, NT-0796, demonstrated positive interim results from its Phase 1 single-ascending dose (SAD) study.
-
NodThera Announces Progress of NT-0796, a Novel NLRP3 Inflammasome Inhibitor, into a Phase 1 First-in-Human Study
11/4/2021
NodThera today announced that the first healthy volunteers have been dosed in a Phase 1 clinical trial of its lead investigational candidate, NT-0796.
-
NodThera Announces Close of $55 Million Series B Financing
6/3/2020
Financing round led by Novo Ventures and includes new investors Cowen Healthcare Investments and Sanofi Ventures, as well as existing investors 5AM Ventures, F-Prime Capital, Sofinnova Partners and founding investor Epidarex Capital
-
U.K.-based NodThera is building up its war chest to develop therapies for diseases driven by chronic inflammation.
-
Nodthera, a U.K.-based startup, snagged $40 million (£28 million) in Series A funding.
-
Epidarex Capital Creates Nodthera Limited
7/28/2016